The endTB consortium has completed endTB-Q, the first Phase 3 randomized controlled trial to exclusively enroll people suffering from pre-extensively drug-resistant tuberculosis (pre-XDR-TB), a very hard-to-treat form of tuberculosis (TB). The trial, conducted by the endTB consortium (Médecins Sans Frontières, Partners In Health, and IRD), demonstrated that a shorter treatment strategy than the conventional treatment and comprised of a combination of four drugs—bedaquiline, clofazimine, delamanid, and linezolid (BCDL)—achieved high cure rates overall and especially good results in the population with non-severe cases of the TB disease.
Clinical trial participants and investigators from India, Kazakhstan and Vietnam share their experiences.